Giovanni Bottegoni / Professore Associato

Giovanni Bottegoni began his scientific career with a master of science in pharmaceutical biotechnology. In 2006, he obtained his doctorate in medicinal chemistry from the Alma Mater Studiorum – University of Bologna, Faculty of Pharmacy. He spent two years as a research fellow the Scripps Research Institute in La Jolla, CA - USA and later joined the Istituto Italiano di Tecnologia (IIT), first as a postdoctoral fellow and eventually as a team leader at the Dept. of Drug Discovery and Development – Computation. In 2014, together with four other scientists, he co-founded BiKi Technologies, an innovative start-up company that develops and commercialises advanced software solutions for computational medicinal chemistry and, for two years, he was CEO of the company. After a stint in industry (Heptares Therapeutics, now SoseiHeptares), he went back to an academic role, joining the School of Pharmacy at the University of Birmingham in 2018 and, eventually, the University of Urbino "Carlo Bo" (Urbino, Italy) as associate professor in medicinal chemistry.

Since 2013, he has been integrating his scientific background and first-hand knowledge of the drug discovery process with managerial skills. In 2014, he obtained a Certificate of Advanced Studies in Management of Biotech, Medtech and Pharma Ventures issued by the École Polytechnique Fédérale de Lausanne (EPFL, CH). In 2015, he completed with honours a master program in International Health Care Management, Economics and Policy (MIHMEP) offered by Bocconi School of Management (Milan, IT).

Prof. Bottegoni has extensive experience in coordinating preclinical drug discovery projects. He co-authored over 50 scientific studies published in international peer-reviewed journals and books and is co-inventor of four patents.

Lunerti V, Li H, Benvenuti F, Shen Q, Domi A, Soverchia L, Concetta Di Martino RM, Bottegoni G, Haass-Koffler CL, Cannella N. The multitarget FAAH inhibitor/D3 partial agonist ARN15381 decreases nicotine self-administration in male rats. Eur J Pharmacol. 2022 Aug 5;928:175088.
 
Di Martino RMC, Cavalli A, Bottegoni G. Dopamine D3 receptor ligands: a patent review (2014-2020). Expert Opin Ther Pat. 2022 Jun;32(6):605-627.
 
Clayton SA, Daley KK, MacDonald L, Fernandez-Vizarra E, Bottegoni G, O'Neil JD, Major T, Griffin D, Zhuang Q, Adewoye AB, Woolcock K, Jones SW, Goodyear C, Elmesmari A, Filer A, Tennant DA, Alivernini S, Buckley CD, Pitceathly RDS, Kurowska-Stolarska M, Clark AR. Inflammation causes remodeling of mitochondrial cytochrome c oxidase mediated by the bifunctional gene C15orf48. Sci Adv. 2021 Dec 10;7(50):eabl5182.

Di Fruscia P., Carbone A., Bottegoni G., Berti F., Giacomina F., Ponzano S., Pagliuca C., Fiasella A., Pizzirani D., Ortega J.A., Nuzzi A., Tarozzo G., Mengatto L., Giampà R., Penna I., Russo D., Romeo E., Summa M., Bertorelli R., Armirotti A., Mandrup Bertozzi S., Reggiani A., Bandiera T., Bertozzi F. Discovery and SAR Evolution of Pyrazole Azabicyclo[3.2.1]octane Sulfonamides as a Novel Class of Non-Covalent N-Acylethanolamine-Hydrolyzing Acid Amidase (NAAA) Inhibitors for Oral Administration 2021 J Med Chem Sep 23;64(18):13327-13355

Di Martino, R.M.C.*, Bottegoni, G.*, Seghetti, F., Russo, D., Penna, I., De Simone, A., Ottonello, G., Mandrup Bertozzi, S., Armirotti, A., Bandiera, T., Belluti, F. and Cavalli, A. Multitarget Compounds for Bipolar Disorder: From Rational Design to Preliminary Pharmacokinetic Evaluation. 2020 ChemMedChem 15(11) 949-954, *equal contribution (front cover)

Ferraro M, Decherchi S, De Simone A, Recanatini M, Cavalli A, Bottegoni G. Multi-Target Dopamine D3 Receptor Modulators: Actionable Knowledge for Drug Design from Molecular Dynamics and Machine Learning 2020 European Journal of Medicinal Chemistry 188:111975